1stOncology™: Cancer Intelligence Service – Page 10044 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Amgen To Present At The Cowen 41st Annual Healthcare Conference

On February 24, 2021 Amgen (NASDAQ:AMGN) reported that it will present at the Cowen 41st Annual Virtual Healthcare Conference at 12:50 p.m. ET on Thursday, March 4, 2021 (Press release, Amgen, FEB 24, 2021, https://investors.amgen.com/news-releases/news-release-details/amgen-present-cowen-41st-annual-healthcare-conference [SID1234575535]). Murdo Gordon, executive vice president of Global Commercial Operations and Peter H. Griffith, executive vice president and chief financial officer at Amgen will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen’s website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen’s website for at least 90 days following the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Lilly to Participate in Cowen Health Care Conference

On February 24, 2021 Eli Lilly and Company (NYSE: LLY) reported that it will participate in the Cowen and Company 41st Annual Health Care Conference on Thursday, March 4, 2021. Daniel Skovronsky, M.D., Ph.D., Lilly’s Chief Scientific Officer and President of Lilly Research Laboratories, will participate in a fireside chat at 9:10 a.m., Eastern Time (Press release, Eli Lilly, FEB 24, 2021, View Source [SID1234575534]).

A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly’s Investor website at View Source A replay of the presentation will be available on this same website for approximately 90 days.

China Rewards Breakthrough Therapy Designation to Innovent & IASO’s CAR-T Cell Therapy

On February 24, 2021 EVERSANA reported The National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE) has granted Breakthrough Therapy Designation (BTD) to Innovent and IASO Biotherapeutics’ investigational CAR-T cell therapy IBI326/CT103A for the treatment of relapsed/refractory (R/R) multiple myeloma (MM) (Press release, EVERSANA, FEB 24, 2021, View Source [SID1234575533]).

IBI326/CT103A is a fully-human anti-B cell maturation antigen (BCMA) targeted CAR-T cell therapy that utilizes lentivirus as a gene vector to transfect autologous T cells, explained Innovent.

In China, BTD is reserved for new medicines that target serious conditions for which clinical evidence suggests the drug in question may demonstrate significant improvement over available therapies.

The CDE elected BTD for IBI326/CT103A based on results from an ongoing Phase 1/2 study of the CAR-T therapy being conducted in R/R MM patients in China—IBI326/CT103A is currently amid a Phase 2 pivotal trial.

Previously, clinical results demonstrating the "impressive" safety, efficacy, and durability of response of IBI326/CT103A as observed in RRMM trials were presented at the 61st Annual Meeting of the American Society for Hematology (ASH) (Free ASH Whitepaper) in 2019.

Dr. Hui Zhou, Vice President of Medical Science and Strategy Oncology at Innovent, commented, "The breakthrough therapy designation from NMPA indicated that IBI326[/CT103A] possesses great potential in treating relapsed or refractory multiple myeloma."

Jinhua Zhang, IASO BIO Founder and CEO, added, "We anticipate expedited development and review in China, allowing more patients with relapsed or refractory multiple myeloma to benefit from this therapy at the earliest possible time."

Cardiff Oncology to Participate in Gastrointestinal (GI) Oncology and Pancreatic Cancer Panel Discussion at the Cowen 41st Annual Health Care Conference

On February 24, 2021 Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer, castrate-resistant prostate cancer and leukemias, reported that Dr. Mark Erlander, chief executive officer of Cardiff Oncology will participate in the upcoming Cowen 41st Annual Health Care Conference taking place March 1-4, 2021 (Press release, Cardiff Oncology, FEB 24, 2021, View Source [SID1234575532]). Dr. Erlander will participate in a GI Oncology and Pancreatic Cancer panel discussion and one-on-one investor meetings at the conference.

Details on the panel discussion can be found below.
Panel Discussion: GI Oncology and Pancreatic Cancer Date and Time:
Tuesday, March 2nd; 9:50 – 10:50 am ET
Webcast: Available for live viewing by conference attendees only

CrownBio and JSR Life Sciences Partner with Cambridge Quantum Computing to Leverage Quantum Machine Learning for Novel Cancer Treatment Biomarker Discovery

On February 24, 2021 Crown Bioscience (CrownBio), JSR Life Sciences and Cambridge Quantum Computing (CQC) reported a partnership agreement to explore the application of quantum technology to drive the identification of multi-gene biomarker discovery for oncology drug discovery (Press release, Crown Bioscience, FEB 24, 2021, View Source [SID1234575531]).

The partnership will combine CrownBio’s domain expertise and vast data sets generated from 15 years of preclinical and translational research and CQC’s advanced capabilities in quantum algorithms, quantum machine learning, and quantum computing.

Utilizing quantum machine algorithms and CQC’s software development framework for execution on NISQ (Noisy Intermediate-Scale Quantum) computers, the initial approach will focus on deriving insight from the analysis of genetic data to identify cancer treatment biomarkers and drive the next generation of bioinformatics.

The objective is to identify a strategy to implement an early quantum computing application that will ultimately address and explore solutions to broad challenges in life sciences.

Armin Spura, CEO of CrownBio commented, "The agreement continues CrownBio’s commitment to innovation and the application of technology to accelerate and de-risk drug development, leading to stronger drug candidates and a more rapid transition from preclinical phases to the clinic."

llyas Khan, CEO of CQC said, "CQC was founded to develop technologies that could help address some of the most pressing societal challenges, particularly in areas such as human biology, so we are excited to enter into our latest partnership with CrownBio to determine how cutting-edge quantum machine learning methods can be applied to critical use cases."